An open-label, pilot study evaluating the efficacy of a lip balm containing panthenol and bisabolol as a monotherapy for the treatment of mild to moderate cheilitis

Phase 4

Recruiting

• Conditions: Patients diagnosed with mild to moderate cheilitis; lip balm, panthenol, bisabolol, cheilitis, treatment

• Registration Number: TCTR20211122002
• Lead Sponsor: Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-22
• Study Completion: 2021-12-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Aged 18 years or older
2. Patients who were diagnosed with mild to moderate cheilitis by dermatologists

Exclusion Criteria

(i) patients with other dermatologic diseases of the lips, (ii) patients with a history of contact allergy to panthenol and bisabolol, (iii) patients applied topical corticosteroids or topical calcineurin inhibitors at the lips 1 week prior to inclusion, (iv) patients taking oral corticosteroids 2 weeks prior to enrollment, and/or (v) pregnant or lactating patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of a lip balm containing panthenol and bisabolol baseline, week 2, week 4, and week 8 ICGS score

Secondary Outcome Measures

Name	Time	Method
The safety of a lip balm containing panthenol and bisabolol baseline, week 2, week 4, and week 8 Adverse events,Physician and patient satisfaction week 8 Product satisfaction score